MITIGATE is launching a clinical trial for patients with metastatic Gastro-Intestinal Stromal Tumours (GIST) who are experiencing tumour progression while under treatment with Imatinib (Glivec®, Gleevec™).

MITIGATE uses an innovative approach focusing on progressive tumour lesions. While the first step of the approach is diagnostic rather than therapeutic, patients may derive real benefits from the imaging procedure, such as improved tumour volume definition and better detection of disease.

If your oncologist later determines that a minimally invasive treatment is advisable for you, then the MITIGATE partners at the University Medical Centre Mannheim (UHEI) and the Medical University of Innsbruck (MUI) can administer such a treatment. The minimally invasive treatment options we offer include trans-arterial procedures like selective internal radiation therapy (SIRT), as well as percutaneous ablations like microwave ablation (MWA) or -- in selected cases -- irreversible electroporation (IRE).

If desired, you may choose another suitable medical centre to perform the procedure. The MITIGATE consortium is continuously working on expanding the network of collaborating institutions providing minimally invasive, radiological interventional treatment based on innovative imaging techniques.

Eligibility Requirements Questionnaire

To determine whether you meet the requirements for participation in our study, please answer the following questions. Note that a patient must meet ALL of the criteria to be eligible for the study. If you have difficulty answering any of the questions or are unsure about an answer, we recommend that you consult with your oncologist.

It is important that you understand that your eligibility for this trial depends on your current therapy. If your disease is currently under control through therapy or if a tumor board has suggested that you undergo a specific therapy, we recommend that you complete this therapy before considering participating in our study.